Boston Scientific, Abbott Offer New Everolimus-Eluting Coronary Stents


September 4, 2008

The FDA recently cleared Boston Scientific Corp.’s PROMUS Everolimus-Eluting Coronary Stent System and Abbott Vascular’s XIENCE V Everolimus Eluting Coronary Stent System, both for the treatment of coronary artery disease.

The PROMUS Stent is a private labeled XIENCE V Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific under an agreement executed prior to the 2006 acquisition of the former Guidant Corp. by Boston Scientific.

Boston Scientific said the PROMUS Stent is highly deliverable, made from cobalt chromium, which allows for thinner struts without sacrificing strength or visibility.

Boston Scientific’s PROMUS Stent and Abbott’s XIENCE V Stent are identical products sold by the respective companies under different brand names. The PROMUS (XIENCE V) Stent is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (up to 28 mm long) with reference vessel diameter of 2.5 to 4.09 mm.